Work

Tryptophan catabolism drives AhR-dependent macropinocytosis and tumorigenesis in tuberous sclerosis complex

Year: 2026
Type: preprint
Abstract: Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by hamartomatous tumors of the brain, skin, kidney and lung (lymphangioleiomyomatosis, LAM). TSC and LAM arise from biallelic inactivation of TSC1 or TSC2 which drives metabolic reprogramming, including macropinocytic scavenging of extracellular nutrients. To determine which nutrients sustain macropinocytosis, we measured dextran uptake after repletion of individual essential amino acids. Unexpectedly, only tryptophan (Trp) stimulated uptake in TSC2-deficient cells by 2.8-fold compared to amino acid-free medium ( p < 0.0001), with no effect in TSC2-expressing cells. Steady-state metabolomics revealed that Trp supplementation raised intracellular Trp by 3.5-fold and lowered kynurenine by 60%. IDO1 inhibition abolished the response, indicating that Trp catabolism rather than Trp itself is the proximal signal. Interestingly, Ido1 , Tdo2 and AhR were markedly upregulated in TSC2-deficient cells, and rapamycin repressed Ido1 and Tdo2 but not AhR . AhR was constitutively nuclear in TSC2-deficient cells, and rapamycin or the AhR antagonist CH-223191 returned it to the cytoplasm. Inhibition of IDO1, (Linrodostat), TDO2 (LM10) or AhR (StemRegenin-1; SR1, CH-223191) selectively decreased macropinocytosis and proliferation of TSC2-deficient cells. AhR antagonism also depleted glutathione by 70%. Treatment of mice with bearing TSC2-deficient tumors with SR1 or CH-223191 reduced tumor volume by approximately 70% and 90% ( p < 0.0001), respectively. Both treatments also strongly decreased mTORC1 activity in tumors, consistent with a model in which macropinocytosis drives mTOR activity in TSC. Collectively, our data identify a Trp-kynurenine-AhR axis that supports macropinocytosis in TSC2-deficient cells, and suggest AhR antagonists as a novel therapeutic approach for the treatment of TSC and LAM. Statement of Significance We show that mTORC1 hyperactivation drives tryptophan catabolism to kynurenine, which activates AhR and sustains macropinocytic nutrient scavenging in TSC2-deficient cells. AhR antagonists suppress tumor growth alone, and more thoroughly with rapamycin. This work identifies a novel therapeutic pathway for patients with TSC and LAM.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7233996784
Cites: 35
Cited by:
Related to: 10